Company / Cash & Equivalents
MAXCYTE, INC. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$20.1M
FY2025
5-year range
$11.1M / $47.8M
FY2021-FY2025
Trend
-28.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $47M to $20M over the past 2 years.
Based on SEC 10-K filings.
$20M in FY2025 with a 3-year CAGR of +21.9%.
Declined from $47M to $20M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +21.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +21.9%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 28.0% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $20.1M | -28.0% |
| FY2024 | $27.9M | -40.0% |
| FY2023 | $46.5M | +320.3% |
| FY2022 | $11.1M | -76.8% |
| FY2021 | $47.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026